株探米国株
英語
エドガーで原本を確認する
6-K 1 bhsc_6k.htm REPORT Report

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2025

 

Commission file number: 001-42389

 

BIOHARVEST SCIENCES INC.

(Exact name of Registrant as specified in its charter)

 

Not applicable

(Translation of Registrant’s name into English)

 

1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

 

 

 


 

SUBMITTED HEREWITH

 

Exhibits:

 

Exhibit

Description

99.1

News Release dated September 2, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BIOHARVEST SCIENCES INC.

 

(Registrant)

 

 

Date: September 2, 2025

/s/ David Ryan

 

Name: David Ryan

 

Title: Vice-President, Investor Relations & Secretary

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EX-99.1 2 bhsc_ex991.htm NEWS RELEASE DATED SEPTEMBER 2, 2025 News Release dated September 2, 2025

BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ET

 

Rehovot, Israel - September 2, 2025 - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will host a Virtual Investor Webinar on Wednesday, September 10, 2025 at 1:00 p.m. Eastern time.

 

CEO Ilan Sobel will host the virtual investor webinar to provide a corporate update on new capability-building initiatives, the Company’s ‘Big Bets’ for 2H 2025, and will conclude with a question-and-answer session from dial-in participants. To attend, please reference the access information below:

 

Virtual Investor Webinar

Date: Wednesday, September 10, 2025

Time: 1:00 p.m. Eastern time

U.S./Canada Dial-in: 1-877-300-8521

International Dial-in: 1-412-317-6026

Conference ID: 10202632

Webcast: BHST Virtual Investor Webinar (https://viavid.webcasts.com/starthere.jsp?ei=1733725&tp_key=4d15ea5c7d)

 

Sobel said: “This upcoming virtual investor webinar provides a fantastic opportunity to discuss new developments across both our consumer and CDMO business units. We look forward to providing a progress update on our ‘Big Bets’ as outlined in our most recent earnings call - such as our Health Pros program, hydration product and key CDMO efforts - as well as dive into exciting new capability-building technology initiatives. As we broaden our product offerings and expand our CDMO pipeline, we remain focused on driving profitable growth and delivering long-term value to my fellow shareholders.”

 

Please dial in at least 10 minutes before the start of the call to ensure timely participation.

 

A telephone playback of the call will be available through Wednesday, September 24, 2025. To listen, call 1-844-512-2921 within the United States and Canada or 1-412-317-6671 when calling internationally, using replay pin number 10202632. A webcast replay will also be available at the webcast link above.

 

About BioHarvest Sciences Inc.

 

BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

 

Forward-Looking Statements

 

Information set forth in this news release might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

 

BioHarvest Corporate Contact:

Dave Ryan, VP Investor Relations MZ Group - MZ North America

(604) 622-1186

info@bioharvest.com


 

 

Investor Relations Contact:

Lucas A. Zimmerman

Managing Director

(949) 259-4987

BHST@mzgroup.us